Layoff file: Charles River, and what the preclinical side is cutting

Most clinical research employers are nearly invisible in the public WARN record. Charles River Laboratories is an exception, which makes its filings worth reading closely. Charles River is not a clinical CRO in the trial-monitoring sense. It is a preclinical, safety-assessment, and manufacturing company that sits upstream of the clinic, doing the nonclinical work that happens before a drug reaches human trials, plus cell and gene therapy manufacturing. When it cuts, the cuts happen at physical sites, which is exactly why they show up in WARN when a clinical CRO's would not.

What the record shows

On the aggregated public filings, Charles River has submitted 16 WARN notices covering roughly 785 employees from 2014 through 2026. The recent activity is concentrated and repeated. Its Wilmington, Massachusetts headquarters has filed round after round through late 2025 and into 2026, in batches of 68 to 71 people at a time. In February 2026 it filed to close a cell therapy manufacturing site in Hanover, Maryland, cutting about 20 and moving client work elsewhere. Older filings cluster in Frederick, Maryland, Durham, North Carolina, and Skokie, Illinois.

None of these are single dramatic events. They are a steady sequence of site-level notices, which is the shape of a company managing margin by trimming its physical footprint over time.

The strategy behind the filings

Charles River has been explicit that it intends to divest underperforming or non-core operations, targeting meaningful annual savings. The cell therapy closure fits that: cell and gene therapy manufacturing was a growth bet across the industry that has cooled, and Charles River is pulling back from part of it. The repeated Wilmington rounds suggest ongoing restructuring at the core rather than one reorganization.

For someone weighing an offer or a move here, the read is straightforward. This is a company in cost discipline, not expansion. That shapes your leverage, how fast a departure gets backfilled, and how exposed a specific site or service line is.

What it tells the clinical side

Charles River is upstream of the clinical audience this site serves, but its record is a useful tell. Preclinical and manufacturing pain often leads clinical pain, because it reflects the same slow pharma R&D spending that eventually reaches the trial-services companies. When the safety-assessment and bioproduction side is filing steadily, the clinical CROs are usually feeling the same budget pressure, even if their distributed workforces keep it out of the WARN record.

What the filing cannot tell you

WARN gives you a location, a count, and a date. It does not tell you which teams, which seniority, or what the severance looked like. It does not tell you whether the people cut landed somewhere better or spent months looking. And for the clinical roles adjacent to this work, it does not tell you anything at all, because those cuts rarely file.

If you work at Charles River or left in one of these rounds, the count in the filing is not the story. What the job market looked like on the way out, and what you were actually paid, is. Post what you can, without naming individuals, and add your datapoint to the survey. The filing has the number. You have the part that matters.